National and institutional leadership and support of NCI-sponsored clinical trial research as a surgical oncologist
Active Project Grant Awarded Last action
- Award ID
- R50CA293523
- Recipient
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $271,614
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 42% complete
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Description
- Abstract
- DR. Akhil chawla plays a pivotal role in the NCI clinical trials program at northwestern university robert h. Lurie comprehensive cancer center (rhlccc). As a surgical oncologist and clinical trial investigator, DR. Chawla has demonstrated a long-term commitment to the support of NCI sponsored studies within at northwestern and nationally through his service and leadership within the alliance for clinical trials in oncology (alliance) and the NCI. DR. Chawla leads the largest pancreatic cancer trial in north america, the alliance A021806 trial, for which he serves as a principal investigator and CO-chair. DR. Chawla has led protocol development, dissemination, implementation, and quality control for this practice-defining trial. As a leader in the NCI cooperative group space, DR. Chawla has significant ambition towards the development of novel and practice changing trials. With his strong dedication to team science, DR. Chawla has leveraged collaboration with experts in his disease space to refine and develop trial concepts he leads. As DR. Chawla has shown unique success within NCI sponsored trial development at such an early point in his career, he has quickly become a leader at northwestern. DR. Chawla continues to be instrumental in rhlccc NCI clinical trial activities, both as an investigator and supporter, including active involvement in protocol assessment, scientific review, and infrastructural expansion of the clinical trials program. With rhlccc's laps grant designation, the NCI- designated cancer program has grown significantly with the expansion of NCI clinical trials into community sites as part of the northwestern medicine health system. DR. Chawla's clinical and investigative footprint spans from northwestern university's academic health campus in chicago to community cancer sites throughout chicagoland. He has leveraged these efforts to become a pioneer within rhlccc and the health system as a known advocate for the dissemination of NCI sponsored clinical trials to geographically remote and underserved populations within the northeastern illinois. DR. Chawla focuses on three major goals at rhlccc: 1) lead integration of rhlccc NCI clinical trials infrastructure across the northwestern medicine health system; 2) increase access and enrollment of racially and geographically diverse populations to NCI clinical trials; and 3) mentor and support junior faculty to participate in NCI-sponsored trial activity at rhlccc and in NCI trial networks. DR. Chawla is uniquely positioned at this point in his career to become a dedicated lifelong supporter and leader of NCI sponsored clinical trials within his institution and throughout the country.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $90,538 | |
| Amendment | $90,538 | |
| Original award | $90,538 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Northwestern Memorial Healthcare | $119,548 |
Quick answers
Who received award R50CA293523?
R50CA293523 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on September 16, 2024.
How much is award R50CA293523 worth?
$271,614 has been obligated on R50CA293523.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award